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L E T T E R  T O  T H E  E D I T O R
House dust mite allergy in Italy—Diagnostic and clinical 
relevance of Der p 23 (and of minor allergens): A real‐life, 
multicenter study
To the Editor,
House dust mites (HDM) are a major cause of respiratory al‐
lergy and of perennial asthma worldwide. Thirty‐two allergens for 
Dermatophagoides farinae (D2) and 21 for Dermatophagoides pteron‐
yssinus (D1) have been detected so far, and novel allergens are still 
being reported.1 Der p 23, a gut‐derived peritrophin present in the 
outer membrane of mite feces,2 has been recognized as a major aller‐
gen.2,3 Der p 1, Der p 2, Der p 23, and Der p 10 (tropomyosin) are the 
only allergens currently available for the component‐resolved diag‐
nosis of HDM allergy on ImmunoCAP. The clinical relevance of Der p 
23 is only partially defined, and the prevalence and relevance of the 
exclusive sensitization to allergens other than groups 1, 2, 10, and 23 
has received little attention so far. We addressed these aspects in a 
large multicenter study.
Seventeen Italian allergy centers (Figure 1 in Data S1) partici‐
pated in this real‐life, cross‐sectional study. Consecutive HDM‐al‐
lergic patients, diagnosed on the basis of history of perennial rhinitis 
with or without asthma and of positive SPT with commercial ex‐
tracts of either D1 or D2, were enrolled between September 1, 2017, 
and June 30, 2018. Rhinitis and asthma were classified following the 
ARIA4 and GINA5 guidelines, respectively. Patients underwent SPT 
also with commercial extracts of an array of other airborne aller‐
gens (see Data S1). IgE specific for D1, D2, Der p 1, Der p 2, Der 
p 10, and Der p 23 was measured by ImmunoCAP (Thermo‐Fisher 
Scientific, Uppsala, Sweden). Levels > 0.35 kU/L were considered 
positive. Sera from patients scoring D1/D2‐positive but negative for 
all 4 allergens underwent immunoblot analysis at Lofarma (Milan, 
Italy) (details in Data S1); the 100 kDa allergen recognized by one 
of these patients was characterized by mass spectrometry (details 
in Data S1). Statistical methods as well as ethical issues are detailed 
in the Data S1; probability levels < 5% were considered statistically 
significant.
A total of 519 patients (M/F: 256/263; mean age 28.4 years, 
range 4‐79) were studied; 221 were monosensitized to HDM, 
while 298 were co‐sensitized to other airborne allergens. Two hun‐
dred and ten (40.5%) had asthma. The prevalence of rhinitis and/
or asthma did not show gender differences although both severe 
rhinitis and moderate/severe asthma prevailed in males. Asthma 
prevalence was similar in the four age groups (0‐19, 20‐39, 40‐59, 
and 60‐79 years), and asthmatic and nonasthmatic patients showed 
a similar mean age. Patients co‐sensitized to other allergens showed 
a higher prevalence of moderate/severe rhinitis (171/298 [57%] vs 
104/221 [47%]; P < 0.05) and of asthma of any severity (132/298 
[44.3%] vs 78/221 [35.3]; P < 0.05) than HDM monosensitized ones.
In vitro, 411/457 (89.9%) scored D1/D2‐positive, 16 (3.5%) and 
5 (1.1%) monosensitized to D1 or D2, respectively, and 23 (5%; F/M 
12/11; 9 with asthma; 8 monosensitized to HDM; 1 with shrimp 
allergy) both D1‐ and D2‐negative. In positive patients, the me‐
dian IgE level was 38.3 and 44.6 kU/L for D1 and D2, respectively. 
Rhinitis severity did not correlate with IgE levels, while asthma 
severity did (P < 0.0001 for both D1 [Figure 1] and D2). IgE to Der 
p 1, Der p 2, Der p 10, and Der p 23 was detected in 58.6%, 67.9%, 
11.9%, and 59.8% of patients, respectively. Sixty‐seven (12.9%; 53 
and 67 positive for D1 and D2, respectively, 35 with moderate/
severe rhinitis, 23 with asthma, and 3 with shrimp allergy) patients 
did not recognize any molecule, whereas 17 (3.3%), 48 (9.3%), 13 
(2.5%), and 42 (8.1%) were monosensitized to Der p 1, Der p 2, 
Der p 10, and Der p 23, respectively. Mean IgE levels to Der p 1 
(19.5 kU/L) and Der p 2 (24.1 kU/L) were significantly higher than 
IgE to Der p 23, which were nonetheless substantial (9.7 kU/L; 
P < 0.001) (for complete data and comparisons, see Table 2 in Data 
F I G U R E  1   Asthma severity and mean level of IgE to 
Dermatophagoides pteronyssinus. NA, nonasthmatic patients
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S1). Der p 23 sensitization prevalence dropped significantly with 
age, being 73%, 55%, 49%, and 35% in the four subgroups, respec‐
tively; accordingly, Der p 23 reactors were younger than negative 
ones (mean age [SD]: 25.6 [14.8] vs 32.6 [17.2]; P < 0.0001). Of 
the 23 D1/D2‐negative patients, 12 reacted to one component: 
Der p 23 in 10 cases and Der p 2 in 2 cases; none bound more 
than one component. Sensitization to either Der p 1, Der p 2, or 
Der p 23 prevailed in central and southern Italy (P < 0.01), while 
patients scoring negative for all four molecules prevailed in the 
north (48/240 [20%] vs 19/279 [7%]; P < 0.0005; details in Table 2, 
Data S1). Mean D1 IgE level was strictly related to the number 
of recombinant allergens recognized (P < 0.0001) and to the level 
of IgE to Der p 1 (r = 0.791), Der p 2 (r = 0.83), and Der p 23 IgE 
(r = 0.66; P < 0.0001 in all three cases). In patients negative for all 
4 components studied, mean D1 IgE level was significantly lower 
than in patients reacting to at least 1 molecule (2.91 ± 6.97 kU/L 
vs 25.75 ± 30.47 kU/L; P < 0.0001). Asthma prevalence did cor‐
relate with the number of recombinant molecules recognized, 
being 30.5%‐34.3%, 50.6%, and 64.7% in patients sensitized to <3, 
3, or all 4 molecules, respectively (r: 0.844; P < 0.05). Patients neg‐
ative for all 4 molecules had less asthma than patients sensitized 
to at least 1 allergen (23/67 [34.3%] vs 183/452 [40.5%]; P < 0.01). 
Further, asthma severity also depended on the number allergen 
components recognized (no asthma < mild < moderate < severe 
asthma; [r = 0.166; P = 0.0001]).
The association between number of molecules recognized 
and asthma was confirmed in patients monosensitized to HDM. 
Asthmatics recognized on average 2.26 molecules vs 1.70 in nonas‐
thmatics (P < 0.005), and the number of components recognized by 
nonasthmatics, patients with mild asthma, or patients with moder‐
ate/severe asthma was 1.79 (SD 1.16), 2.06 (1.14), and 2,58 (0.99), 
respectively (P < 0.05 for moderate/severe vs mild asthma and 
P < 0.001 for moderate/severe asthmatic vs nonasthmatic patients).
In monosensitized patients, asthma was strongly associated with 
Der p 23 hypersensitivity (58/78 [74%] vs 66/143 [46%]; P < 0.0005; 
[OR: 3.38 at 95% CI]); such association lacked for the other 3 aller‐
gens (Figure 2). Further, asthma severity was associated with Der p 
23 IgE levels (P < 0.0001), which were 3.9 kU/L (SD 9.5), 5.9 kU/L 
(10.4), 11.0 (17.1), and 17.8 (20.3) in nonasthmatic patients, and pa‐
tients with slight, moderate, or severe persistent asthma, respec‐
tively. On immunoblot (performed using all 27 available sera out of 
67 patients who did not react to any component), most sera reacted 
to high mw HDM allergens ranging between 80 and 220 kDa (Figure 
in Data S1); the allergen detected by LC‐MS‐MS in one single patient 
was identified as paramyosin (mw, about 100 kDa).
This study shows that asthma prevails in multisensitized patients 
suggesting an increased inflammation of lower airways in this sub‐
population. Further, it confirms that asthma prevalence and severity 
depend on the number of HDM molecules recognized.6,7 The higher 
severity of rhinitis and asthma in males needs further investigation. In 
vitro studies show that measuring both D1 and D2 IgE is needed to 
diagnose HDM allergy, as 5% are monosensitized. However, D1/D2‐
negative patients are often Der p 23 reactors confirming that Der p 
23 is underrepresented in HDM extracts.9 Further, HDM allergy diag‐
nosis cannot rely on the current panel of components only as 13% of 
patients react to currently unavailable high mw allergens, one of them 
being the muscle protein, paramyosin, as previously observed.10 Der p 
23 is a major allergen, is clearly associated with asthma and its preva‐
lence drops with age; long‐term, follow‐up studies in young HDM‐al‐
lergic patients will clarify whether sensitization is lost with age or if 
Der p 23 is a novel allergen that has become relevant in recent years.
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F I G U R E  2   Association between asthma ad hypersensitivity to 
specific molecules in patients monosensitized to house dust mites. 
A clear association with Der p 23 hypersensitivity is observed. Left 
column: asthmatic patients; right column: nonasthmatic patients
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